INVESTOR DEADLINE TOMORROW: TransMedics Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TMDX

Core Viewpoint - The TransMedics Group, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934 due to misleading statements and unsafe practices during the specified class period [1][3]. Group 1: Class Action Details - The class action lawsuit is titled Jewik v. TransMedics Group, Inc., and it allows investors who purchased TransMedics securities between February 28, 2023, and January 10, 2025, to seek appointment as lead plaintiff by April 15, 2025 [1][6]. - The lawsuit alleges that TransMedics engaged in unethical practices, including kickbacks and fraudulent overbilling, which contributed to a lack of safety oversight [3][5]. Group 2: Allegations and Impact - On February 21, 2024, U.S. Representative Paul Gosar accused TransMedics of misconduct, leading to a decline in the company's stock price following media coverage of the allegations [4]. - A report from Scorpion Capital on January 10, 2025, further accused TransMedics of overbilling and providing rejected organs to patients, resulting in another drop in stock price [5]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and has a strong track record in securing monetary relief for investors in securities fraud cases [7].